2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Tuesday, October 23, 2018

9:00AM-11:00AM: Abstract Number: 2298

Developing a Classification Criteria for Cutaneous Dermatomyositis Utilizing the Delphi Technique

Muscle Biology, Myositis and Myopathies Poster III: Treatment and Classification Criteria

9:00AM-11:00AM: Abstract Number: 2181

Development and Feasibility of a Web-Based Data Capture System to Collect Uniform Comprehensive Post-Total Knee Replacement Physical Therapy Intervention Data for Both Clinical and Research Purposes

Health Services Research Poster III – ACR/ARHP

9:00AM-11:00AM: Abstract Number: 2671

Development and First-in-Human Characterization of an ICOSL and BAFF Bispecific Inhibitor AMG 570 for SLE Treatment

Systemic Lupus Erythematosus – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2474

Development of a Crosswalk for FACIT-10 (Psychometric Work)

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III: Complications of Therapy, Outcomes, and Measures

9:00AM-11:00AM: Abstract Number: 2141

Development of a Pediatric Glucocorticoid Toxicity Index

Epidemiology and Public Health Poster III: SLE, SSc, APS, PsA, and Other Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 2514

Development of a Subcutaneous Formulation of CT-P13 (Infliximab): Maintenance Subcutaneous Administration May Elicit Lower Immunogenicity Compared to Intravenous Treatment

Rheumatoid Arthritis – Treatments Poster III: Biosimilars and New Compounds

9:00AM-11:00AM: Abstract Number: 2155

Diagnosis of Systemic Sclerosis in the United Kingdom: An Observational Study Using the Clinical Practice Research Datalink

Epidemiology and Public Health Poster III: SLE, SSc, APS, PsA, and Other Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 2773

Diagnostic and Therapeutic Management of a Suspected Case of GCA: An Opinion Survey

Vasculitis Poster III: Immunosuppressive Therapy in Giant Cell Arteritis and Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 2321

Dickkopf-1 Serum Levels in Patients with Systemic Sclerosis and Correlation with Trabecular Bone Score

Osteoporosis and Metabolic Bone Disease – Basic and Clinical Science Poster

9:00AM-11:00AM: Abstract Number: 2180

Differences in Longitudinal Disease Activity Measures between Research Cohort and Non-Cohort Participants with Rheumatoid Arthritis Using Electronic Health Record Data

Health Services Research Poster III – ACR/ARHP

9:00AM-11:00AM: Abstract Number: 2023

Different Patterns of Interferon-Response-Gene Expression May Elucidate Different Pathomechanisms That Drive IFN-Response-Gene Activation in Patients with Presumed IFN-Mediated Autoinflammatory Diseases

Pediatric Rheumatology – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 2673

Different Risk Profiles for Development of Steroid-Related and Steroid-Unrelated Damage in Early Diagnosed SLE: Results from the Italian Multicenter Early Lupus Project Inception Cohort

Systemic Lupus Erythematosus – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2263

Differentiated Phenotypes at Diagnosis of Sarcoidosis According to the Scadding Classification: Analysis in 1230 Patients

Miscellaneous Rheumatic and Inflammatory Diseases Poster III: Sarcoid, Inflammatory Eye Disease, and Autoinflammatory Disease

9:00AM-11:00AM: Abstract Number: 2185

Direct Medical Costs for Medicare Patients with Rheumatoid Arthritis

Health Services Research Poster III – ACR/ARHP

9:00AM-11:00AM: Abstract Number: 2706

Discriminant Validity and Reliability of World Scleroderma Foundation (WSF) Definition of Skin Ulcers in Systemic Sclerosis

Systemic Sclerosis and Related Disorders – Clinical Poster III

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].